Oral Antidiabetic Treatment Market

Introduction

Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from  this many other diabetics case are also been listed as gestational diabetes and others.

The world is moving toward the diabetic’s world according to the International Diabetes Federation 415 million people are diabetes in 2015. This directly affect the market to come up with new innovations for diagnosis and treatment.

The main cause of diabetes is the unstable lifestyle habits of the population which include physical inactivity, unhealthy diet, obesity, and smoking and in some cases the family history is also the strong risk of the diabetes. Various treatment method are present in the market injection, oral and others. The mostly used method of treatment or managing the diabetes is the oral.

Oral Antidiabetic (OAD) Treatment Market: Drivers & Restraints

Oral antidiabetic treatment is the most widely used method in the market, many players are coming with various product in the market. For instance, in August 2015, Glenmark Pharmaceuticals Limited has lunched generic Teneligliptin which was a third-generation oral anti-diabetic drug.

The awareness program is also going by various private and government organization. The research organization are also working in antidiabetic sector to come up with various generation of diagnosis and treatment.  The higher costing of the drugs is the hindrance of the market.

Oral Antidiabetic (OAD) Treatment Market: Segmentation

Drug Type	Sulphonylureas Biguanides Intestinal α-glucosidase inhibitors Others
End User	Hospital Pharmacy Store Drug Store Diabetics Treatment Centres Others
Geography	North America Europe Latin America Asia-Pacific Middle East and Africa

Regional Outlook

As a geography conditions the Oral Antidiabetic (OAD) Treatment Market is segmented into: North America, Latin America, Europe, Asia-Pacific and the Middle East & Africa. North America has the 44.3 million population with diabetes in 2015 according to the IDF, same as Europe have 59.8 million in 2015 according to IDF and Asia Pacific has 60% diabetic population as compared with world according to Asian Diabetes Prevention Initiative.

Key Players

Some players in Oral Antidiabetic (OAD) Treatment Market are Eli Lilly and Company, AstraZeneca, Glenmark Pharmaceuticals Limited Novo Nordisk A/S, MSD & Co., Inc., Mannkind Corporation and Sanofi.

The report covers exhaustive analysis on:

• Oral Antidiabetic (OAD) Treatment Market Segments
• Oral Antidiabetic (OAD) Treatment Market Dynamics
• Historical Actual Market Size, 2013 - 2016
• Oral Antidiabetic (OAD) Treatment Market Size & Forecast 2017 to 2025
• Oral Antidiabetic (OAD) Treatment Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Oral Antidiabetic (OAD) Treatment Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

To know more about delivery timeline for this report Contact Sales